But you know what, this is better to write on the requisition and make sure it’s included. If you look at primary breast cancers versus metastatic from the IMpassion130 trial, a higher percentage of the primary deposit for PD-L1 versus metastatic. The metastatic is like mid-40...
Rosenblum: It does. And you added a whole dimension in thinking about how it has downstream positive effects. Griggs: You mentioned that it's been 3 months between your previous appointment and yesterday's appointment. I'm wondering what that's been like for you. Rosenblum: Well, after 20...
Although sacituzumab is looking like it’s superior, I don’t know that we could say much about the TPC arms in a head-tohead comparison here. I think this all looks pretty consistent with what physician practice would be in the drugs that we choose.3 How does germline BRCA status ...
What is an area you would like to see addressed? What are you hoping community oncologists apply to practice? If you treat women in the first-line setting at diagnosis of metastatic recurrence, response rates can be 25%. It is important to enroll women in clinical trials as early as possi...
Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.
And if they progress further, probably a clinical trial or maybe something like eribulin. GAIN: At every stage, I would try to put them on a clinical trial first because I don’t think it matters what you use. For second-line therapy, I think you have to look up at how...
Kahl: Dr. Kaklamani, it sounds like we're making a lot of strides in this space, which is great. So, in particular, what does this mean for this patient population? Dr. Virginia G. Kaklamani: Well, we've been able to show that we can improve patient survival by giving them ...
Claudine Isaacs, MD:I would echo what has been said. Obviously, we’re looking at immunotherapy as well, and we’ll get to that in a few moments. Just to go back to Hope’s presentation from the CALGB trial, you know, overall, we remember that trial. It was trying to look at ixab...